Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
CURIS INC | Director | Non Qualified Stock Option | 85K | $988K | $11.62 | Jan 31, 2022 | Direct |
Enliven Therapeutics, Inc. | Director | Common Stock | 31.2K | $605K | $19.40 | Apr 8, 2024 | Indirect |
Oric Pharmaceuticals, Inc. | Director | Common Stock | 68.7K | $435K | $6.33 | Mar 3, 2025 | Direct |
Enliven Therapeutics, Inc. | Director | Common Stock | 14.8K | $286K | $19.40 | Apr 8, 2024 | Direct |
Nurix Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $21.57 | Jul 17, 2024 | Direct |
Nurix Therapeutics, Inc. | Director | Director Stock Option (right to buy) | 25K | May 20, 2024 | Direct | ||
Enliven Therapeutics, Inc. | Director | Stock Option (right to buy) | 15.4K | Feb 6, 2025 | Direct | ||
Oric Pharmaceuticals, Inc. | Director | Stock Option (right to buy) | 0 | Mar 3, 2025 | Direct |